Teva Concedes On US Gimoti ANDA, Voiding 180-Day Exclusivity
Change Of ANDA Certification Could Mean Years Added To Brand Monopoly
Executive Summary
Teva will not engage in paragraph IV patent-infringement litigation with Evoke Pharma over the originator’s Gimoti (metoclopramide) nasal spray treatment for diabetic gastroparesis, following a court order.
You may also be interested in...
Top 10 Things To Watch For At DDW
At Digestive Disease Week, Celltrion will seek to strengthen its hold on the IBD market, Ironwood hopes to expand Linzess into pediatric functional constipation, and competitors will showcase competing short bowel syndrome treatment and colorectal cancer companion diagnostics.
Big Pharma Shouts, Generics And Biosimilars Whisper: M&A In 2023
“A lot of companies are hurting because of the higher interest rates,” one major CEO observed recently, summing up a year which saw little headline-grabbing news on the M&A front for generic and biosimilar sponsors.
Lupin Looks To Be First Out Of The Blocks On US Ingrezza, With Zydus Second
ANDA sponsors targeting Neurocrine Biosciences’ Ingrezza (valbenazine) blockbuster are in position to launch – albeit with a 14-year wait that validates the strength of the originator’s IP.